Statil (BioDeep_00000387535)

   


代谢物信息卡片


PONALRESTAT

化学式: C17H12BrFN2O3 (390.0015274)
中文名称: 波来瑞斯
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1=CC=C2C(=C1)C(=NN(C2=O)CC3=C(C=C(C=C3)Br)F)CC(=O)O
InChI: InChI=1S/C17H12BrFN2O3/c18-11-6-5-10(14(19)7-11)9-21-17(24)13-4-2-1-3-12(13)15(20-21)8-16(22)23/h1-7H,8-9H2,(H,22,23)

描述信息

C471 - Enzyme Inhibitor > C72880 - Aldose Reductase Inhibitor
D007004 - Hypoglycemic Agents
D004791 - Enzyme Inhibitors

同义名列表

2 个代谢物同义名

PONALRESTAT; Statil



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. Cell reports. 2021 04; 35(4):109040. doi: 10.1016/j.celrep.2021.109040. [PMID: 33910017]
  • Ying Zhu, Hong-Jiang Li, Qi Su, Jing Wen, Yuefan Wang, Wen Song, Yinpeng Xie, Wenrong He, Zhen Yang, Kai Jiang, Hongwei Guo. A phenotype-directed chemical screen identifies ponalrestat as an inhibitor of the plant flavin monooxygenase YUCCA in auxin biosynthesis. The Journal of biological chemistry. 2019 12; 294(52):19923-19933. doi: 10.1074/jbc.ra119.010480. [PMID: 31732559]
  • Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology. 2019 11; 96(5):629-640. doi: 10.1124/mol.119.115964. [PMID: 31515284]
  • Zhe Cao, Boping Zhou, Xinchun Chen, Dan Huang, Xiuli Zhang, Ziqi Wang, Hua Huang, Yuhong Wang, Deliang Cao. Statil suppresses cancer cell growth and proliferation by the inhibition of tumor marker AKR1B10. Anti-cancer drugs. 2014 Sep; 25(8):930-7. doi: 10.1097/cad.0000000000000121. [PMID: 24800887]
  • E M Lenz, I D Wilson, B Wright, E A Partridge, C T Rodgers, P R Haycock, J C Lindon, J K Nicholson. A comparison of quantitative NMR and radiolabelling studies of the metabolism and excretion of Statil (3-(4-bromo-2-fluorobenzyl)-4-oxo-3H-phthalazin-1-ylacetic acid) in the rat. Journal of pharmaceutical and biomedical analysis. 2002 Apr; 28(1):31-43. doi: 10.1016/s0731-7085(01)00637-9. [PMID: 11861106]
  • I Kawamura, N Yamamoto, F Sakai, H Yamazaki, T Goto. Effect of lipoprotein lipase activators bezafibrate and NO-1886, on B16 melanoma-induced cachexia in mice. Anticancer research. 1999 Sep; 19(5B):4099-103. doi: ". [PMID: 10628360]
  • I Kawamura, E Lacey, M Inami, F Nishigaki, Y Naoe, S Tsujimoto, T Manda, T Goto. Ponalrestat, an aldose reductase inhibitor, inhibits cachexia syndrome in nude mice bearing human melanomas G361 and SEKI. Anticancer research. 1999 Sep; 19(5B):4091-7. doi: ". [PMID: 10628359]
  • I Kawamura, N Yamamoto, F Sakai, H Yamazaki, Y Naoe, M Inami, T Manda, K Shimomura. Activation of lipoprotein lipase and inhibition of B16 melanoma-induced cachexia in mice by ponalrestat, an aldose reductase inhibitor. Anticancer research. 1999 Jan; 19(1A):341-8. doi: ". [PMID: 10226565]
  • P Martin, I D Wilson. Comparison of the properties of polymeric and C8 based materials for solid phase extraction. Journal of pharmaceutical and biomedical analysis. 1998 Sep; 17(6-7):1093-100. doi: 10.1016/s0731-7085(98)00075-2. [PMID: 9884199]
  • P Martin, E D Morgan, I D Wilson. An investigation of the properties of a 'shielded' phase for the solid phase extraction of acidic and basic compounds. Journal of pharmaceutical and biomedical analysis. 1996 Feb; 14(4):419-27. doi: 10.1016/0731-7085(95)01647-3. [PMID: 8729640]
  • K Mimura, F Umeda, T Yamashita, K Kobayashi, T Hashimoto, H Nawata. Effects of glucose and an aldose reductase inhibitor on albumin permeation through a layer of cultured bovine vascular endothelial cells. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 1995 Oct; 27(10):442-6. doi: 10.1055/s-2007-979998. [PMID: 8575721]
  • T Soulis-Liparota, M E Cooper, M Dunlop, G Jerums. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia. 1995 Apr; 38(4):387-94. doi: 10.1007/bf00410275. [PMID: 7796978]
  • N A Calcutt, A P Mizisin, M W Kalichman. Aldose reductase inhibition, Doppler flux and conduction in diabetic rat nerve. European journal of pharmacology. 1994 Jan; 251(1):27-33. doi: 10.1016/0014-2999(94)90439-1. [PMID: 8137868]
  • A S Reddi, G N Jyothirmayi. Aldose reductase inhibition by ponalrestat (statil) does not prevent proteinuria in long-term diabetic rats. Journal of diabetes and its complications. 1993 Oct; 7(4):233-40. doi: 10.1016/s0002-9610(05)80250-8. [PMID: 8219366]
  • S A Phillips, D Mirrlees, P J Thornalley. Modification of the glyoxalase system in streptozotocin-induced diabetic rats. Effect of the aldose reductase inhibitor Statil. Biochemical pharmacology. 1993 Sep; 46(5):805-11. doi: 10.1016/0006-2952(93)90488-i. [PMID: 8373434]
  • G Faiman, P Ganguly, A Mehta, J A Thliveris. Effect of statil on kidney structure, function and polyol accumulation in diabetes mellitus. Molecular and cellular biochemistry. 1993 Aug; 125(1):27-33. doi: 10.1007/bf00926831. [PMID: 8264569]
  • M Kunisaki, F Umeda, T Yamauchi, M Masakado, H Nawata. High glucose reduces specific binding for D-alpha-tocopherol in cultured aortic endothelial cells. Diabetes. 1993 Aug; 42(8):1138-46. doi: 10.2337/diab.42.8.1138. [PMID: 8325444]
  • S Sato, P F Kador. Human kidney aldose and aldehyde reductases. Journal of diabetes and its complications. 1993 Jul; 7(3):179-87. doi: 10.1016/1056-8727(93)90043-x. [PMID: 8343612]
  • S Ranganathan, M Krempf, E Feraille, B Charbonnel. Short term effect of an aldose reductase inhibitor on urinary albumin excretion rate (UAER) and glomerular filtration rate (GFR) in type 1 diabetic patients with incipient nephropathy. Diabete & metabolisme. 1993 Mar; 19(2):257-61. doi: NULL. [PMID: 8339858]
  • S Lightman. Does aldose reductase have a role in the development of the ocular complications of diabetes?. Eye (London, England). 1993; 7 ( Pt 2)(?):238-41. doi: 10.1038/eye.1993.56. [PMID: 7607342]
  • J Y Chien, C R Banfield, R K Brazzell, P R Mayer, J T Slattery. Saturable tissue binding and imirestat pharmacokinetics in rats. Pharmaceutical research. 1992 Apr; 9(4):469-73. doi: 10.1023/a:1015880011131. [PMID: 1495891]
  • A Beyer-Mears, F T Murray, E Cruz, J Rountree, M Sciadini. Comparison of sorbinil and ponalrestat (Statil) diminution of proteinuria in the BB rat. Pharmacology. 1992; 45(5):285-91. doi: 10.1159/000139012. [PMID: 1465475]
  • A Ghahary, S Chakrabarti, A A Sima, L J Murphy. Effect of insulin and statil on aldose reductase expression in diabetic rats. Diabetes. 1991 Nov; 40(11):1391-6. doi: 10.2337/diab.40.11.1391. [PMID: 1936600]
  • M W Bradbury, S L Lightman, L Yuen, G G Pinter. Permeability of blood-brain and blood-nerve barriers in experimental diabetes mellitus in the anaesthetized rat. Experimental physiology. 1991 Nov; 76(6):887-98. doi: 10.1113/expphysiol.1991.sp003551. [PMID: 1768415]
  • R F Moulds, R O Fullinfaw, R W Bury, W E Plehwe, N Jacka, K M McGrath, F I Martin. Ponalrestat does not cause a protein binding interaction with warfarin in diabetic patients. British journal of clinical pharmacology. 1991 Jun; 31(6):715-8. doi: 10.1111/j.1365-2125.1991.tb05601.x. [PMID: 1907841]
  • B S Daniels, T H Hostetter. Functional and structural alterations of the glomerular permeability barrier in experimental galactosemia. Kidney international. 1991 Jun; 39(6):1104-11. doi: 10.1038/ki.1991.140. [PMID: 1910123]
  • M M Pedersen, J S Christiansen, C E Mogensen. Reduction of glomerular hyperfiltration in normoalbuminuric IDDM patients by 6 mo of aldose reductase inhibition. Diabetes. 1991 May; 40(5):527-31. doi: 10.2337/diab.40.5.527. [PMID: 1902426]
  • W P Chang, E Dimitriadis, T Allen, M E Dunlop, M Cooper, R G Larkins. The effect of aldose reductase inhibitors on glomerular prostaglandin production and urinary albumin excretion in experimental diabetes mellitus. Diabetologia. 1991 Apr; 34(4):225-31. doi: 10.1007/bf00405080. [PMID: 1906023]
  • P Passa, H Leblanc, B Billault. [Prevention of terminal kidney failure in insulin-dependent diabetics. Current status and prospects]. Presse medicale (Paris, France : 1983). 1991 Mar; 20(10):471-5. doi: NULL. [PMID: 1827179]
  • B L Mylari, T A Beyer, T W Siegel. A highly specific aldose reductase inhibitor, ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate, and its congeners. Journal of medicinal chemistry. 1991 Mar; 34(3):1011-8. doi: 10.1021/jm00107a020. [PMID: 1900532]
  • B L Mylari, E R Larson, T A Beyer, W J Zembrowski, C E Aldinger, M F Dee, T W Siegel, D H Singleton. Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners. Journal of medicinal chemistry. 1991 Jan; 34(1):108-22. doi: 10.1021/jm00105a018. [PMID: 1899452]
  • S Sato, P F Kador. Inhibition of aldehyde reductase by aldose reductase inhibitors. Biochemical pharmacology. 1990 Sep; 40(5):1033-42. doi: 10.1016/0006-2952(90)90490-c. [PMID: 2117925]
  • A Bhatnagar, S Q Liu, B Das, N H Ansari, S K Srivastava. Inhibition kinetics of human kidney aldose and aldehyde reductases by aldose reductase inhibitors. Biochemical pharmacology. 1990 Mar; 39(6):1115-24. doi: 10.1016/0006-2952(90)90292-s. [PMID: 2157439]
  • W H Ward, C M Sennitt, H Ross, A Dingle, D Timms, D J Mirrlees, D P Tuffin. Ponalrestat: a potent and specific inhibitor of aldose reductase. Biochemical pharmacology. 1990 Jan; 39(2):337-46. doi: 10.1016/0006-2952(90)90033-h. [PMID: 2105733]
  • R Rasch, R Osterby. No influence of an aldose reductase inhibitor on glycogen deposition in tubules from streptozotocin diabetic rats. The Journal of diabetic complications. 1989 Oct; 3(4):198-201. doi: 10.1016/0891-6632(89)90030-5. [PMID: 2533211]
  • B S Daniels, T H Hostetter. Aldose reductase inhibition and glomerular abnormalities in diabetic rats. Diabetes. 1989 Aug; 38(8):981-6. doi: 10.2337/diab.38.8.981. [PMID: 2502460]
  • R Osterby, H J Gundersen. Glomerular basement membrane thickening in streptozotocin diabetic rats despite treatment with an aldose reductase inhibitor. The Journal of diabetic complications. 1989 Jul; 3(3):149-53. doi: 10.1016/0891-6632(89)90037-8. [PMID: 2528558]
  • M Sochor, S Kunjara, P McLean. The effect of aldose reductase inhibitor Statil (ICI 128436) on the glucose over-utilization in kidney of diabetic rats. Biochemical pharmacology. 1988 Sep; 37(17):3349-56. doi: 10.1016/0006-2952(88)90649-1. [PMID: 2969732]
  • R Poulsom, M Kurkinen, D J Prockop, R P Boot-Handford. Increased steady-state levels of laminin B1 mRNA in kidneys of long-term streptozotocin-diabetic rats. No effect of an aldose reductase inhibitor. The Journal of biological chemistry. 1988 Jul; 263(21):10072-6. doi: 10.1016/s0021-9258(19)81478-3. [PMID: 2839472]
  • R Poulsom. Inhibition of aldose reductase from human retina. Current eye research. 1987 Mar; 6(3):427-32. doi: 10.3109/02713688709025198. [PMID: 3107906]
  • D Stribling, D J Mirrlees, H E Harrison, D C Earl. Properties of ICI 128,436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat. Metabolism: clinical and experimental. 1985 Apr; 34(4):336-44. doi: 10.1016/0026-0495(85)90223-9. [PMID: 3920474]